Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

POLE/POLD1 mutation and tumor immunotherapy.

Journal of experimental & clinical cancer research : CR - 2 Jul 2022

Ma Xiaoting, Dong Lin, Liu Xiu, Ou Kai, Yang Lin

Abstract excerpt

POLE and POLD1 encode the catalytic and proofreading subunits of DNA polymerase ε and polymerase δ, and play important roles in DNA replication and proofreading. POLE/POLD1 exonuclease domain mutations lead to loss of proofreading function, which causes the accumulation of mutant genes in cells. POLE/POLD1 mutations are not only closely related to tumor formation, but are also a potential molecular marker for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to DNA Polymerase II
Share to DNA Polymerase III

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic factors in colorectal cancer

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Poly-ADP-Ribose Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35780178
DOI: 10.1186/s13046-022-02422-1
PMCID: PMC9250176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

POLE/POLD1 mutation and tumor immunotherapy.PMID 35780178Read ↗

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitorSemantic proximity Read ↗

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapySemantic proximity Read ↗

Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.Semantic proximity Read ↗

A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.Semantic proximity Read ↗

The game-changing impact of POLE mutations in oncology—a review from a gynecologic oncology perspectiveSemantic proximity Read ↗

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.Semantic proximity Read ↗

Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.Semantic proximity Read ↗

Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinomaSemantic proximity Read ↗

From Subtle to Severe: Multiple Mechanisms Impair POLE and POLD1 Function leading to Distinct Effects on Mutation RatesSemantic proximity Read ↗

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.Semantic proximity Read ↗

Beyond proofreading: POLD1 mutations as dynamic orchestrators of genomic instability and immune evasion in cancerSemantic proximity Read ↗

Comprehensive characterization of DNA polymerases driver variants using large genomic datasetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.